▶ 調査レポート

予測遺伝学のグローバル市場(~2027):素因検査、発症前検査

• 英文タイトル:Predictive Genetics Market Research Report by Type, Demographics, Test Type, Setting Type, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Predictive Genetics Market Research Report by Type, Demographics, Test Type, Setting Type, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「予測遺伝学のグローバル市場(~2027):素因検査、発症前検査」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2304A044
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、239ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の当調査レポートでは、2021年に897.21百万ドルであった世界の予測遺伝学市場規模が2022年に1,058.98百万ドルへと拡大、更に2027年までにCAGR 18.20%で成長して2,447.68百万ドルに達すると予測しています。当書は、予測遺伝学の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析(素因検査、発症前検査)、デモグラフィック別分析(35~64歳、65歳以上、35歳以下)、検査種類別分析(人口スクリーニング、感受性検査)、施設別分析(クリニック、D2C(消費者直接)、病院)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの構成でまとめています。なお、当書には、23andMe、Color Genomics、CRISPR Therapeutics、Deep Genomics Inc.、Editas Medicine、Futura Genetics、Gene by Gene、Intellia Therapeutics、Laboratory Corporation of America、Mapmygenome India、MyDNA、Myriad Genetics、Positive Bioscience、Quest Diagnostics, Inc.、Veritas Geneticsなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の予測遺伝学市場規模:種類別
- 素因検査の市場規模
- 発症前検査の市場規模
・世界の予測遺伝学市場規模:デモグラフィック別
- 35~64歳における市場規模
- 65歳以上における市場規模
- 35歳以下における市場規模
・世界の予測遺伝学市場規模:検査種類別
- 人口スクリーニングの市場規模
- 感受性検査の市場規模
・世界の予測遺伝学市場規模:施設別
- クリニックにおける市場規模
- D2C(消費者直接)における市場規模
- 病院における市場規模
・世界の予測遺伝学市場規模:地域別
- 南北アメリカの予測遺伝学市場規模
アメリカの予測遺伝学市場規模
カナダの予測遺伝学市場規模
ブラジルの予測遺伝学市場規模
...
- アジア太平洋の予測遺伝学市場規模
日本の予測遺伝学市場規模
中国の予測遺伝学市場規模
インドの予測遺伝学市場規模
韓国の予測遺伝学市場規模
台湾の予測遺伝学市場規模
...
- ヨーロッパ/中東/アフリカの予測遺伝学市場規模
イギリスの予測遺伝学市場規模
ドイツの予測遺伝学市場規模
フランスの予測遺伝学市場規模
ロシアの予測遺伝学市場規模
...
- その他地域の予測遺伝学市場規模
・競争状況
・企業情報

The Global Predictive Genetics Market size was estimated at USD 897.21 million in 2021 and expected to reach USD 1,058.98 million in 2022, and is projected to grow at a CAGR 18.20% to reach USD 2,447.68 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Predictive Genetics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Predispositional testing and Presymptomatic testing.

Based on Demographics, the market was studied across 35 – 64, 65+, and <35. Based on Test Type, the market was studied across Population Screening and Susceptibility. Based on Setting Type, the market was studied across Clinic, Direct to Consumer, and Hospital. Based on Application, the market was studied across Cancer, Cardiovascular Disease, and Genetic Disease. Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market. Cumulative Impact of 2022 Russia Ukraine Conflict: We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Predictive Genetics market considering the current update on the conflict and its global response. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Predictive Genetics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. Competitive Scenario: The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service. Company Usability Profiles: The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Predictive Genetics Market, including 23andMe, Color Genomics, CRISPR Therapeutics, Deep Genomics Inc., Editas Medicine, Futura Genetics, Gene by Gene, Intellia Therapeutics, Laboratory Corporation of America, Mapmygenome India, MyDNA, Myriad Genetics, Positive Bioscience, Quest Diagnostics, Inc., and Veritas Genetics. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global Predictive Genetics Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Predictive Genetics Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Predictive Genetics Market? 4. What is the competitive strategic window for opportunities in the Global Predictive Genetics Market? 5. What are the technology trends and regulatory frameworks in the Global Predictive Genetics Market? 6. What is the market share of the leading vendors in the Global Predictive Genetics Market? 7. What modes and strategic moves are considered suitable for entering the Global Predictive Genetics Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing use of emerging technologies to gain valuable insights
5.1.1.2. Adopted for new and growing class of medical tests, differing in fundamental ways from conventional medical diagnostic tests
5.1.1.3. Reduces the risk of a specific condition will lead to reduced morbidity and mortality through targeted screening, surveillance, and prevention
5.1.2. Restraints
5.1.2.1. Lack of skilled workforce
5.1.3. Opportunities
5.1.3.1. Need of genetic predisposition DNA testing for type 2 diabetes and
5.1.3.2. Rising investment and R&D in gene manipulation
5.1.4. Challenges
5.1.4.1. Companies’ concern over data security and privacy issues
5.2. Cumulative Impact of COVID-19

6. Predictive Genetics Market, by Type
6.1. Introduction
6.2. Predispositional testing
6.3. Presymptomatic testing

7. Predictive Genetics Market, by Demographics
7.1. Introduction
7.2. 35 – 64
7.3. 65+
7.4. <35 8. Predictive Genetics Market, by Test Type 8.1. Introduction 8.2. Population Screening 8.3. Susceptibility 9. Predictive Genetics Market, by Setting Type 9.1. Introduction 9.2. Clinic 9.3. Direct to Consumer 9.4. Hospital 10. Predictive Genetics Market, by Application 10.1. Introduction 10.2. Cancer 10.3. Cardiovascular Disease 10.4. Genetic Disease 11. Americas Predictive Genetics Market 11.1. Introduction 11.2. Argentina 11.3. Brazil 11.4. Canada 11.5. Mexico 11.6. United States 12. Asia-Pacific Predictive Genetics Market 12.1. Introduction 12.2. Australia 12.3. China 12.4. India 12.5. Indonesia 12.6. Japan 12.7. Malaysia 12.8. Philippines 12.9. Singapore 12.10. South Korea 12.11. Taiwan 12.12. Thailand 12.13. Vietnam 13. Europe, Middle East & Africa Predictive Genetics Market 13.1. Introduction 13.2. Denmark 13.3. Egypt 13.4. Finland 13.5. France 13.6. Germany 13.7. Israel 13.8. Italy 13.9. Netherlands 13.10. Nigeria 13.11. Norway 13.12. Poland 13.13. Qatar 13.14. Russia 13.15. Saudi Arabia 13.16. South Africa 13.17. Spain 13.18. Sweden 13.19. Switzerland 13.20. Turkey 13.21. United Arab Emirates 13.22. United Kingdom 14. Competitive Landscape 14.1. FPNV Positioning Matrix 14.1.1. Quadrants 14.1.2. Business Strategy 14.1.3. Product Satisfaction 14.2. Market Ranking Analysis, By Key Player 14.3. Market Share Analysis, By Key Player 14.4. Competitive Scenario 14.4.1. Merger & Acquisition 14.4.2. Agreement, Collaboration, & Partnership 14.4.3. New Product Launch & Enhancement 14.4.4. Investment & Funding 14.4.5. Award, Recognition, & Expansion 15. Company Usability Profiles 15.1. 23andMe 15.1.1. Business Overview 15.1.2. Key Executives 15.1.3. Product & Services 15.2. Color Genomics 15.2.1. Business Overview 15.2.2. Key Executives 15.2.3. Product & Services 15.3. CRISPR Therapeutics 15.3.1. Business Overview 15.3.2. Key Executives 15.3.3. Product & Services 15.4. Deep Genomics Inc. 15.4.1. Business Overview 15.4.2. Key Executives 15.4.3. Product & Services 15.5. Editas Medicine 15.5.1. Business Overview 15.5.2. Key Executives 15.5.3. Product & Services 15.6. Futura Genetics 15.6.1. Business Overview 15.6.2. Key Executives 15.6.3. Product & Services 15.7. Gene by Gene 15.7.1. Business Overview 15.7.2. Key Executives 15.7.3. Product & Services 15.8. Intellia Therapeutics 15.8.1. Business Overview 15.8.2. Key Executives 15.8.3. Product & Services 15.9. Laboratory Corporation of America 15.9.1. Business Overview 15.9.2. Key Executives 15.9.3. Product & Services 15.10. Mapmygenome India 15.10.1. Business Overview 15.10.2. Key Executives 15.10.3. Product & Services 15.11. MyDNA 15.11.1. Business Overview 15.11.2. Key Executives 15.11.3. Product & Services 15.12. Myriad Genetics 15.12.1. Business Overview 15.12.2. Key Executives 15.12.3. Product & Services 15.13. Positive Bioscience 15.13.1. Business Overview 15.13.2. Key Executives 15.13.3. Product & Services 15.14. Quest Diagnostics, Inc. 15.14.1. Business Overview 15.14.2. Key Executives 15.14.3. Product & Services 15.15. Veritas Genetics 15.15.1. Business Overview 15.15.2. Key Executives 15.15.3. Product & Services 16. Appendix 16.1. Discussion Guide 16.2. License & Pricing